
    
      Randomized double-blind placebo controlled intervention study in children with TSC between
      age 4 and 15 years with an intelligence quotient (IQ) estimated <80 and/or special schooling
      and/or autism spectrum disorder and/or learning disability requiring remedial teaching.

      Patients are randomised to receive everolimus or placebo during a period of 12 months.
    
  